PRM-151 Therapy Well Tolerated In Patients With Advanced Myelofibrosis
A study that investigated the potential of the compound PRM-151 (PRM)
for reducing progressive bone marrow fibrosis (scarring) in patients
with advanced myelofibrosis has shown initial positive results.
Myelofibrosis is a life-threatening bone marrow cancer.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news